1. Myelofibrosis patients in Belgium: disease characteristics. Issue 2 (April 2015) Authors: Devos, T.; Zachée, P.; Bron, D.; Noens, L.; Droogenbroeck, J. Van; Mineur, P.; Beguin, Y.; Berneman, Z.; Benghiat, F. S.; Kentos, A.; Chatelain, C.; Demuynck, H.; Lemmens, J.; Eygen, K. Van; Theunissen, K.; Trullemans, F.; Pierre, P.; Pluymers, W.; Knoops, L. Journal: Acta clinica belgica Issue: Volume 70:Issue 2(2015) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. Issue 1 (February 2015) Authors: Beguin, Y.; Selleslag, D.; Meers, S.; Graux, C.; Bries, G.; Deeren, D.; Vrelust, I.; Ravoet, C.; Theunissen, K.; Voelter, V.; Potier, H.; Trullemans, F.; Noens, L.; Mineur, P. Journal: Acta clinica belgica Issue: Volume 70:Issue 1(2015) Page Start: 34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THE 5‐YEAR FOLLOW‐UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA. (June 2017) Authors: Ghesquieres, H.; Tilly, H.; Sonet, A.; Dupuis, J.; Nicolas‐Virelizier, E.; Andre, M.; Trullemans, F.; Eisenmann, J.; Delarue, R.; Fleck, E.; Morschhauser, F.; Blay, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 198 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗